Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Other material
confidence 65%
filed 2026-06-11
The filing discloses a press release announcing 30-day results from the CGUARDIANS II clinical trial of the CGuard Prime 80 cm implant for TCAR procedures. This is a clinical trial result disclosure under Item 7.01 (Regulation FD Disclosure). While clinical trial results can be material to investors in medical device companies, this does not fit neatly into the standard taxonomy categories (not an earnings release, not a restatement, not litigation, etc.), making "other_material" the most appropriate classification.
View raw filing on EDGAR →
8-K
M&A activity
confidence 45%
filed 2026-06-11
The filing discloses a material restructuring of the Company's debt obligations under Item 2.03 (Creation of a Direct Financial Obligation). Nakamoto Inc. executed a Restructured Loan Term Sheet with Kraken on June 5, 2026, for 210,000,000 USDT secured by 4,405 Bitcoin, followed by a Partial Repayment of $45 million and a subsequent June Term Sheet for 165,000,000 USDT. While Item 2.03 typically signals covenant_breach or debt restructuring, the magnitude and complexity of this multi-tranche loan restructuring—involving collateral maintenance thresholds, liquidation triggers, and material asset pledges—resembles a material financing transaction. However, the core event is the creation of a direct financial obligation (debt restructuring) rather than an acquisition or change of control, making this ambiguous between covenant_breach, ma_activity, and other_material.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-11
The filing discloses entry into a material supply agreement (Item 1.01) between TechForce Robotics (a wholly-owned subsidiary) and Jiun Jiang Enterprise for manufacturing robotic systems. While this is a supply/manufacturing agreement rather than a traditional M&A transaction, the three-year initial term with auto-renewal, IP licensing framework, and strategic manufacturing partnership suggest materiality. However, the lack of financial terms, deal value, or strategic context makes it difficult to assess whether this rises to the level of a traditional "material acquisition" or is better classified as a significant operational/commercial arrangement outside the standard taxonomy.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 92%
filed 2026-06-11
The filing's principal disclosure under Item 5.02 is an Amended and Restated Compensation Agreement with CEO Kevin O'Donnell, effective June 5, 2026. The agreement specifies a $550,000 annual base salary, a one-time $875,000 cash bonus, elimination of future annual bonus opportunities, and detailed severance and termination provisions. This is a material compensatory arrangement modification for a named executive officer that would affect investor assessment of executive pay and retention incentives.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-11
The filing discloses results of the 2026 Annual Meeting of Stockholders held on June 11, 2026, under Item 5.07. Three proposals were voted upon: (1) election of Lucille Salhany as a Class III director, (2) advisory approval of executive compensation for fiscal year 2025, and (3) ratification of WithumSmith+Brown, PC as independent auditors for 2026. All three proposals passed with clear majorities. This is a standard shareholder vote results disclosure that is material to investors as it reflects governance decisions and auditor appointment.
View raw filing on EDGAR →
8-K
Exec departure
confidence 92%
filed 2026-06-11
Eric Kash resigned as Executive Vice President and Board member effective June 5, 2026. While the filing also discloses severance terms ($125,000 in installments, vested stock options, and accrued vacation), the principal disclosed action is the departure itself. The resignation was not due to disagreement, and the severance arrangement is ancillary to the departure event. This is material as executive departures affect investor assessment of management stability and governance.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-11
The filing discloses results of Reed's, Inc.'s 2026 annual meeting of stockholders held on June 10, 2026, including voting outcomes on director elections, auditor ratification, approval of the 2026 Equity Incentive Plan, and advisory votes on executive compensation. Item 5.07 explicitly presents vote tallies (for, against, abstentions, broker non-votes) for each matter, which is the core disclosure requirement for shareholder vote results. While the filing also addresses executive compensation plan approval under Item 5.02(e), the primary substantive disclosure is the shareholder voting results themselves.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-11
AIM ImmunoTech entered into a securities purchase agreement on June 9, 2026, to issue 2,554,119 registered shares at $0.5189 per share (approximately $1.3 million gross proceeds) and concurrently issued 771,503 unregistered shares plus pre-funded warrants and Class J warrants in a private placement. The filing explicitly discloses unregistered equity issuances under Item 3.02, with warrants exercisable for up to 12 million additional shares, representing substantial dilution to existing shareholders and a material capital raise typical of small-cap equity financings.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-11
Item 5.07 discloses the results of Omega Flex's Annual Meeting of Shareholders held on June 10, 2026, with voting results for the election of three Class 3 directors (James M. Dubin, Kevin R. Hoben, and Dean W. Rivest). The filing's primary substantive disclosure is the shareholder vote outcome, which is material to investors as it confirms board composition and governance continuity.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-11
The filing discloses results of an extraordinary general meeting held on June 11, 2026, where shareholders voted on and approved an amendment to extend the business combination deadline from June 14, 2026 to December 31, 2026. The vote tabulation shows 2,723,387 votes for, 4,376 against, and 17 abstentions, with 2,727,780 shares represented constituting a quorum. This is a classic Item 5.07 shareholder vote result disclosure, material to investors as it directly affects the timeline for the company's proposed business combination with Shenzhen Qianzhi BioTechnology Co. Ltd.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-11
The filing discloses a one-for-ten reverse stock split of Shuttle Pharmaceuticals' common stock, effective June 11, 2026, authorized by stockholders at the May 21, 2026 annual meeting and implemented by board action on June 1, 2026. While reverse stock splits are typically administrative in nature, this event is material to investors as it affects share count, exercise prices of warrants and convertible securities, and trading mechanics on Nasdaq. The event does not fit neatly into the specific taxonomy categories (it is not an earnings release, executive change, M&A activity, restatement, auditor change, going concern, impairment, shareholder vote results, delisting risk, bankruptcy, covenant breach, cybersecurity incident, dilutive issuance, or material litigation), making "other_material" the most appropriate classification.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-06-11
The filing discloses a material sale-leaseback transaction under Item 1.01 (Entry into a Material Definitive Agreement). On June 5, 2026, the Company's subsidiary sold approximately 9.5 acres of land underlying the Ford Amphitheater to O'Neil Roth Ford, LLC for $49.7 million in cash and a $19.88 million promissory note, with concurrent entry into a new 25-year ground lease at increased annual rent of $4.224 million. This constitutes a material disposition of a significant operating asset, with related financing and equity issuance (5 million warrants at $3.79/share), affecting the Company's capital structure and liquidity.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-06-11
The 8-K discloses under Item 7.01 (Regulation FD Disclosure) that Laser Photonics issued a press release regarding "financial results and accomplishments achieved during the quarter ended March 31, 2026." The press release is furnished as Exhibit 99.1. This is a standard earnings release disclosure for Q1 2026 results, which is material to investors assessing the company's financial performance.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-11
The filing discloses Item 5.07 results from U.S. GoldMining's June 11, 2026 annual meeting of stockholders, including voting results for the election of six directors (Alastair Still, Garnet Dawson, Ross Sherlock, Lisa Wade, Laura Schmidt, and Aleksandra Bukacheva) and ratification of Deloitte LLP as independent auditor. This is a standard shareholder vote results disclosure that materially informs investors of board composition and auditor approval.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-06-11
The filing's primary substantive disclosure under Item 5.02 is the appointment of Jordan Zwick to the Board of Directors on June 10, 2026, expanding the Board from five to six directors. While the filing also covers shareholder vote results (Item 5.07) and equity plan amendments, the appointment of a new director with Audit Committee assignment is the most salient executive personnel action disclosed and would be material to investors assessing board composition and governance.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-11
The filing discloses a private placement of 96,000,000 shares of common stock for $300,000 in cash pursuant to Subscription Agreements executed on June 6 and June 11, 2026, with institutional and accredited investors under Section 4(a)(2) and Rule 506(b) exemptions. This represents a highly dilutive unregistered equity issuance at a minimal valuation ($0.003125 per share), which is material to investors assessing the registrant's capital structure and shareholder value.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-11
Item 5.07
Arq, Inc. held its Annual Meeting of Stockholders and disclosed voting results on five proposals: election of six directors, advisory vote on executive compensation, ratification of auditor Baker Tilly US, LLP, approval of the 2026 Omnibus Incentive Plan, and approval of the Ninth Amendment to the Tax Asset Protection Plan. All proposals passed with substantial majorities.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-11
Item 5.07
Marqeta held its 2026 Annual Meeting of Shareholders on June 10, 2026, with final voting results disclosed for five proposals: election of four Class II directors, ratification of KPMG LLP as auditor, approval of a 1-for-4 reverse stock split, officer exculpation amendment, and advisory vote on named executive officer compensation.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-11
Item 8.01
Shareholders approved and the Board authorized a 1-for-4 reverse stock split with a corresponding reduction in authorized shares, a structural corporate action affecting the company's share structure and capitalization.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-11
Item 8.01
This Item 8.01 discloses the issuance and sale of approximately $832.6 million in commercial mortgage pass-through certificates (BANK5 2026-5YR22) by Wells Fargo Commercial Mortgage Securities, Inc., including publicly offered certificates ($735.8M) and privately offered certificates ($96.8M), along with detailed credit risk retention compliance under Regulation RR. While this is a material securitization transaction affecting the registrant's capital structure and investor base, it does not fit neatly into the standard 8-K event taxonomy (not an M&A activity, earnings release, or other specifically enumerated event type), making "other_material" the most appropriate classification.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-06-11
Item 1.01
The filing discloses entry into a material definitive agreement—the Pooling and Servicing Agreement dated May 1, 2026, establishing Wells Fargo Commercial Mortgage Trust 2026-5C9 and the issuance of Commercial Mortgage Pass-Through Certificates backed by 29 fixed-rate mortgage loans and subordinate interests in 2 commercial mortgage loans. This represents a securitization transaction involving the creation of an issuing entity and transfer of material assets, which constitutes M&A-like activity requiring Item 1.01 disclosure. The subsequent transfer of The Towers at Cupertino City Center Mortgage Loan to the BANK5 2026-5YR22 securitization further evidences material asset disposition activity.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-11
Item 5.07
This Item 5.07 discloses the results of Carlyle Secured Lending's 2026 Annual Meeting of Stockholders held on June 9, 2026, including voting outcomes for the election of two Class I directors (Linda Pace and William H. Wright II) and ratification of Ernst & Young LLP as independent auditor. The filing presents detailed vote tallies (For/Withhold/Broker Non-Votes) for each proposal, all of which were approved by requisite vote. This is a standard shareholder vote results disclosure material to investors' understanding of corporate governance.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-11
Item 5.07
This is a clear disclosure of shareholder vote results from a Special Meeting held on June 9, 2026. The filing reports the final voting tallies (26,328,719 for, 7,457,315 against, 2,023,401 abstain) on a proposal to authorize the Company to issue shares below net asset value over the next 12 months. The proposal was approved by the requisite vote. This is material because authorization to issue dilutive equity at below-NAV prices directly affects shareholder value and capital structure.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-11
Item 8.01
Nurix disclosed updated Phase 1a/1b clinical trial data for its lead BTK degrader bexobrutideg (NX-5948) in CLL/SLL patients, presented at EHA2026, including expanded safety findings across 142 patients and an 83% objective response rate in relapsed/refractory patients, along with new Phase 1b cohort data in earlier-line treatment settings.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-11
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of Airbnb's 2026 Annual Meeting of Stockholders held on June 5, 2026. The filing presents voting outcomes on seven proposals: election of three Class III directors (Blecharczyk, Lin, Manyika), ratification of PwC as auditor, advisory vote on named executive officer compensation, and four stockholder proposals (all defeated). The detailed vote tallies for each proposal are the core content of the disclosure, making this a textbook shareholder_vote_results event that is material to investors assessing board composition and governance outcomes.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-11
Item 5.07
This is a classic Item 5.07 disclosure of shareholder meeting results. The filing reports the outcomes of three proposals voted on at Caesars Entertainment's June 9, 2026 Annual Meeting: election of 11 directors (all elected by majority vote), advisory approval of named executive officer compensation (85.7% approval), and ratification of Deloitte & Touche LLP as independent auditor (99.8% approval). The detailed vote tallies and percentages are the core content of the disclosure.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-11
Item 7.01
Summit Therapeutics withdrew a previously announced underwritten public offering effective June 10, 2026 due to market conditions. While the withdrawal itself is disclosed under Item 7.01 (Other Events), the cancellation of a planned capital raise signals material market or financial stress that would affect investor assessment of the company's liquidity and strategic position. This does not fit neatly into the dilutive_issuance category (which covers completed or announced offerings) but represents a material change in the company's financing plans.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 92%
filed 2026-06-11
Item 5.02
Shareholders approved the Fifth Amended and Restated 2019 Equity Incentive Plan, increasing authorized shares by 565,000 for equity compensation purposes to officers and directors.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-11
Item 5.07
Weatherford held a Special Court-Convened Meeting and 2026 Annual General Meeting on June 11, 2026, with voting results on six director elections, auditor ratification, executive compensation approval, equity plan approval, and a failed redomestication proposal from Ireland to Texas that did not achieve the required 75% threshold.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-11
Item 8.01
Caribou Biosciences announced clinical trial data from two ongoing phase 1 trials: ANTLER for vispa-cel in relapsed/refractory B-cell non-Hodgkin lymphoma (82% ORR, 67% CR) and CaMMouflage for CB-011 in relapsed/refractory multiple myeloma (92% ORR, 83% ≥CR). The data, presented at the EHA 2026 Annual Meeting, demonstrates progress toward planned phase 3 trials and is material to investors assessing the company's pipeline advancement and regulatory pathway.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-11
Item 7.01
Philip Morris announced a regular quarterly dividend of $1.47 per share via press release on June 11, 2026, disclosed under Item 7.01 (Regulation FD Disclosure). While dividend declarations are routine corporate actions, they are material to shareholders as they affect total shareholder return and cash flow expectations. This does not fit the earnings_release category (which typically reports financial results) nor any other specific event type in the taxonomy, making other_material the most appropriate classification.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-06-11
Item 2.02
The filing discloses a press release announcing The Lovesac Company's financial results for the first quarter of fiscal year 2027 (ended May 3, 2026), filed under Item 2.02 (Results of Operations and Financial Condition). This is a classic earnings release disclosure, which is material to investors as it provides periodic financial performance information.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-11
Item 8.01
C4 Therapeutics disclosed positive Phase 1 trial data for cemsidomide in combination with dexamethasone for relapsed/refractory multiple myeloma, presented via a poster at EHA 2026 Congress and accompanied by a press release. This clinical trial progress is material to the company's pipeline prospects and would affect a reasonable investor's assessment of the registrant's development stage and competitive position.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-06-11
Item 2.02
The filing discloses an earnings press release for the quarterly period ended May 2, 2026, issued on June 11, 2026, and furnished as Exhibit 99.1. This is a standard quarterly earnings release disclosure under Item 2.02, which is material to investors as it provides financial results and operational performance for the period.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-11
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of Ovid Therapeutics' annual meeting of stockholders held on June 10, 2026. The filing presents voting results for three proposals: (1) election of director Jeremy M. Levin (87.2M votes for, 8.5M withheld), (2) advisory approval of named executive officer compensation (84.5M for, 8.9M against), and (3) ratification of KPMG LLP as auditor (130.8M for, 32.5K against). These are routine annual meeting matters that materially inform shareholders about governance and management approval.
View raw filing on EDGAR →
8-K
Other material
confidence 70%
filed 2026-06-11
Item 1.01
Blue Owl Credit Income Corp. completed a $500 million debt offering on June 11, 2026, pursuant to a Purchase Agreement dated June 8, 2026, with proceeds to be used to pay down existing indebtedness. This material capital structure event was disclosed under Item 1.01 (Entry into a Material Definitive Agreement) and Item 2.03 (Creation of a Direct Financial Obligation), representing a significant refinancing or debt restructuring transaction.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-06-11
Item 5.02
The filing discloses amendments to compensatory arrangements for two named executives: Lachlan K. Murdoch (Executive Chair and CEO) and Steven Tomsic (CFO). The Committee and Board approved increases in target annual bonuses and equity awards for both executives, as well as extensions of their employment terms through June 30, 2030. This is a classic executive compensation disclosure under Item 5.02(e), distinct from a departure or appointment, and is material to investors assessing executive incentive structures and retention.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-06-11
Item 5.02
Eric Park was appointed Chief Accounting Officer effective June 8, 2026, assuming the role of principal accounting officer. While the disclosure also includes compensatory arrangements (base salary increase to $300,000, bonus target of $200,000, and a $175,000 PRSU award), the principal disclosed action is the appointment itself. The appointment of a principal accounting officer is material to investors as it affects the registrant's financial reporting oversight and governance structure.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-11
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of IMAX Corporation's 2026 Annual General Meeting of Shareholders held on June 10, 2026. The filing presents voting results on three matters: election of ten directors, appointment of PricewaterhouseCoopers LLP as independent auditors, and an advisory say-on-pay vote on Named Executive Officer compensation. All three outcomes are material to shareholders' understanding of corporate governance and management accountability.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-06-11
Item 3.01
GoHealth received a written notice from Nasdaq on June 9, 2026 determining to delist the Company's Class A common stock (GOCO) from Nasdaq, effective June 16, 2026. The delisting was based on the Chapter 11 bankruptcy filing, concerns about residual equity interests, and failure to maintain the $35 million minimum market value requirement under Nasdaq Listing Rule 5550(b)(2). This is a direct and material delisting event that removes the company's primary listing venue.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-11
Item 5.07
This is a classic Item 5.07 disclosure reporting the final results of voting at Magnite's 2026 annual stockholder meeting held on June 8, 2026. The filing presents voting tallies for four proposals: election of three Class III directors (Paul Caine, Doug Knopper, David Pearson), ratification of Deloitte & Touche LLP as auditor, advisory approval of named executive officer compensation, and advisory frequency vote on future compensation votes. All proposals passed. This is a material event as shareholder meeting outcomes affect corporate governance and investor confidence.
View raw filing on EDGAR →
8-K
Auditor Change
confidence 98%
filed 2026-06-11
Item 4.01
The filing discloses the dismissal of BDO USA, P.C. as the Company's independent registered public accounting firm effective June 5, 2026, and the simultaneous appointment of Deloitte & Touche LLP as the new auditor. This is a classic auditor change under Item 4.01. The materiality is heightened by the disclosure of material weaknesses in internal control over financial reporting in both 2024 and 2025, including adverse audit opinions and ongoing control deficiencies in revenue, inventory, and segregation of duties.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-11
Item 5.07
This Item 5.07 disclosure reports the final results of Limbach Holdings' June 9, 2026 annual meeting of stockholders, including voting outcomes on four proposals: election of three Class A directors (Horowitz, Alvarado, Dugan), non-binding advisory approval of named executive officer compensation, frequency of say-on-pay votes, and ratification of Crowe LLP as independent auditor. The detailed vote tallies (For/Against/Abstain/Broker Non-Votes) for each proposal are the core content, making this a textbook shareholder_vote_results disclosure.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-11
Item 5.07
Yext held its annual meeting of stockholders on June 10, 2026, at which shareholders voted on four proposals: election of Class III directors (Daniel Englander and Andrew Sheehan), ratification of Ernst & Young LLP as independent auditor, advisory approval of named executive officer compensation, and approval of the 2016 Equity Incentive Plan, as amended, restated and extended.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-11
Item 5.07
Acadian Asset Management held its Annual Meeting on June 11, 2026, with shareholders voting on four proposals: election of five directors, ratification of KPMG LLP as independent auditor, advisory vote on executive compensation, and approval of the 2026 Equity Incentive Plan. The filing discloses detailed voting tallies for all four proposals.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-11
Item 5.07
Pacira BioSciences held its Annual Meeting of Stockholders on June 9, 2026, with detailed voting results disclosed for five proposals: election of three Class III directors (including contested nominees), ratification of KPMG LLP as auditor, advisory vote on named executive officer compensation, and approval of two equity plans.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 75%
filed 2026-06-11
Item 5.02
Stockholders approved an Amended and Restated 2014 Employee Stock Purchase Plan (ESPP) with an increase of 800,000 newly reserved shares, a material compensatory arrangement affecting equity incentives available to employees.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-11
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of Alight's 2026 Annual Meeting of Stockholders held on June 10, 2026. The filing presents detailed vote tallies for six proposals: election of Class II directors (Fradin, Lopes, Massey), ratification of Ernst & Young LLP as auditor, advisory approval of named executive officer compensation, board declassification amendment, officer liability limitation amendment, and reverse stock split authorization. All proposals passed. The disclosure is material as it documents stockholder approval of significant corporate governance changes (board declassification, officer liability protection) and strategic actions (reverse split authorization).
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-06-11
Item 2.02
Lennar Corporation issued a press release on June 11, 2026 announcing results of operations for the second quarter ended May 31, 2026, filed under Item 2.02 (Results of Operations and Financial Condition). This is a standard quarterly earnings release disclosure with the press release furnished as Exhibit 99.1, which is material to investors assessing the company's financial performance.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-11
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of Western Alliance Bancorporation's Annual Meeting of Stockholders held on June 10, 2026. The filing presents voting outcomes for three proposals: election of thirteen directors, advisory vote on executive compensation, and ratification of RSM US LLP as independent auditor. All three proposals passed with substantial majorities, and the disclosure includes detailed vote tallies (for, against, abstentions, broker non-votes) for each matter, which is the standard format for shareholder vote results disclosures.
View raw filing on EDGAR →